Intellia Therapeutics begins Phase III trial of hereditary angioedema gene therapy
Variation in the frequency of hereditary angioedema attacks between weeks five and 28 will be the trial's primary endpoint.
Clinical Trials
Johnson & Johnson discontinues Phase III study of treatment for bladder cancer
AstraZeneca’s Phase III trial of treatment for asthma meets its primary endpoint
University of Queensland advances spider venom-derived heart drug to trials
Microbiotica initiates subject dosing in Phase Ib melanoma therapy trial
TiumBio doses first participant in Phase II trial of immuno-oncology drug
FDA places hold on Kezar Life Sciences’ trial for lupus nephritis treatment
Immutep concludes participant enrolment in Phase II breast cancer trial
